Clinical trials: Diabetes Mellitus ( Type 1 and Type 2)
Coronary Artery Calcification
Toe-brachial Index and Coronary Calcification in Type 1 and 2 Diabetes
Diabetes is not a coronary risk equivalent, despite cardiovascular disease is the most common cause of death in diabetes. So, to identify diabetic patients at high cardiovascular risk is necessary.
- Trial name
- ACCoDiab (NCT03920683)
- Testing
- Data collection
- Where
- France
- Volunteers
- 707 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetes, Type 1, Diabetes, Type 2
The Relationship of Hemoglobin A1c and Diabetic Wound Healing
The purpose of this study is to investigate the relationship of hemoglobin A1c in diabetic wound healing. Additionally, a comparison of two wound dressings, AmeriGel® (Amerx Health Care Corp., Clearwater, FL) and Bacitracin, with…
- Conditions
- Diabetes, Type 1, Diabetes, Type 2, Foot Ulcer, Diabetic
- Trial name
- NCT01350102
- Testing
- Bacitracin, AmeriGel®, Vitamin C
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Susan Hassenbein
Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2
Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)
The purpose of this study is to determine the key factors influencing insulin sensitivity in type 1 diabetes (T1DM) and maturity onset diabetes of the young, type 2 (MODY2).
- Conditions
- Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
- Trial name
- NCT02971202
- Testing
- Hyperinsulinemic, euglycemic clamp, 20% dextrose
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
This is a randomized, active- and placebo-controlled, double-blind trial of MK-5160 in participants with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). This is a two-part trial, with three panels per part.
- Trial name
- NCT03095651
- Testing
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the pharmacokinetics, tolerability, and safety of single and multiple doses of exenatide once-weekly suspension via subcutaneous (SC) injection using a pre-filled, single-dose autoinjector…
- Trial name
- NCT04001231
- Testing
- Exenatide Once-Weekly Suspension
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
The Characteristics of Different Personal Lancets on Blood Volume and Perceived Pain in Patients With Diabetes Mellitus
A randomized single-blind study with the use of different lancing devices equipped with personal lancets to determine and to compare the amount of capillary blood volume and perceived pain after a single lancing of the fingertip.
- Trial name
- NCT04253431
- Testing
- Droplet lancing device (HTL-Strefa S.A.), Microlet 2 lancing device (Bayer), OneTouch Delicia lancing device (LifeScan)
- Volunteers
- 60 people
- Sponsor
- HTL-Strefa S.A.
Diabetes Mellitus, Type 2
A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)
This study compares semaglutide in two different injection tools called "PDS290" and "DV3372". The study aims to show similar levels of semaglutide in the blood when using either of the two injection tools.
- Trial name
- NCT03611322
- Testing
- Semaglutide, 0.25 mg, Semaglutide, 0.5 mg, Semaglutide, 1.0 mg
- Where
- Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus
To compare the efficacy (in terms of metabolic control evaluated through HbA1c levels) of treatment with insulin glargine as basal insulin and insulin analogue (insulin lispro) as mealtime insulin with a regimen of insulin NPH as…
- Trial name
- NCT00537251
- Testing
- Insulin glargine
- Volunteers
- 80 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
AI-Predicted Disease Trajectories in Diabetes: A Retrospective Study
The study explores the utilization of artificial intelligence (AI) to predict disease progression trajectories in patients with diabetes.
- Trial name
- AI-TRYDIA (NCT06280729)
- Testing
- AI-Analyis
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- IRCCS San Raffaele
Type 1 Diabetes (T1D), Type 2 Diabetes
Capillary OGTT Study
Type 1 diabetes (T1D) is a chronic condition, affecting 1 in 490 children under the age of 15 years. It is caused by the immune system damaging the pancreas, the organ which makes insulin.
- Trial name
- CapOGTT (NCT06815081)
- Where
- 4 sites in United Kingdom
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Type 1 Diabetes Mellitus
Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D).
- Trial name
- TIRTLE2 (NCT06820281)
- Testing
- Tirzepatide 2.5mg weekly
- Where
- Australia
- Volunteers
- 44 people
- Sponsor
- Victor Chang Cardiac Research Institute
Diabete Mellitus, Autoimmune Diabetes
Differentiating Heart Disease Between Adult-onset Autoimmune and Type 2 Diabetes
Background: The study of factors associated with diabetic heart disease (DHD), the leading cause of mortality in diabetes, represents an unmet need.
- Conditions
- Diabete Mellitus, Autoimmune Diabetes, Latent Autoimmune Diabetes in Adult (LADA), Type 2 Diabetes
- Trial name
- HD DIAB (NCT07911007)
- Testing
- Cardiac Magnetic Resonance
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Roma La Sapienza
Type 2 Diabetes
An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System
A multi-center, single-arm, open-label study to evaluate the safety and effectiveness of the EndoBarrier Gastrointestinal Liner System liner on glycemic control in control subjects from study #09-1 who are not treatment failures…
- Trial name
- OLE (NCT02293720)
- Testing
- EndoBarrier
- Sponsor
- Morphic Medical Inc.
Kidney Transplant Recipients
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.
- Trial name
- HALLMARK (NCT05938712)
- Testing
- Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Type 2 Diabetes, Overweight or Obesity
Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT05814107
- Testing
- CT-996
- Where
- 2 sites in Australia, Mexico
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Carmot Australia First Pty Ltd
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes.
- Trial name
- YKAA (NCT06945406)
- Testing
- LY4057996 SC, LY4057996 IV, Degludec SC
- Where
- Germany
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the pharmacodynamics (the effect of the investigated drug on the body) and pharmacokinetics (the exposure of the trial drug in the body) of insulin degludec…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01865292
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Levemir® Used as Basal Insulin
This study is conducted in Europe. The aim of this study is to evaluate efficacy and safety of insulin detemir (Levemir®) used as basal insulin on the glycaemic control, weight and incidence of hypoglycaemic events in insulin…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01548248
- Testing
- insulin detemir, insulin aspart
- Where
- Slovakia
- Volunteers
- 631 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
This study is an open label, prospective, randomised comparative, single center study. In the present study, the impact of a 12-week pulsatile insulin infusion therapy (PIT) with Humulin R 100 from
- Trial name
- NCT04030091
- Testing
- 3 hours humulin R 100 IU/mL PIT, 2 hours humulin R 100 IU/mL PIT
- Where
- 2 sites in United States, Germany
- Volunteers
- 24 people
- Sponsor
- Sciema UG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.